Cargando…

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

Molecular targeted therapies are the standard of care for front‐line treatment of metastatic non‐small‐cell lung cancers (NSCLCs) harboring driver gene mutations. However, despite the initial dramatic responses, the emergence of acquired resistance is inevitable. Acquisition of secondary mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koga, Takamasa, Suda, Kenichi, Mitsudomi, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898722/ https://www.ncbi.nlm.nih.gov/pubmed/34997674 http://dx.doi.org/10.1111/cas.15263

Ejemplares similares

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021)

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
por: Suda, Kenichi, et al.
Publicado: (2020)

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
por: Ohara, Shuta, et al.
Publicado: (2020)

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
por: Koga, Takamasa, et al.
Publicado: (2023)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection
por: Tomizawa, Kenji, et al.
Publicado: (2015)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
por: Mizuuchi, Hiroshi, et al.
Publicado: (2016)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
por: Suda, Kenichi, et al.
Publicado: (2014)

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
por: Sato, Katsuaki, et al.
Publicado: (2016)

Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
por: Ohara, Shuta, et al.
Publicado: (2019)

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
por: Hamada, Akira, et al.
Publicado: (2022)

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
por: Suda, Kenichi, et al.
Publicado: (2019)

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
por: Suda, Kenichi, et al.
Publicado: (2017)

Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe
por: Tomizawa, Kenji, et al.
Publicado: (2015)

Novel mechanism of resistance to targeted therapies in lung cancer
por: Wang, Walter, et al.
Publicado: (2018)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
por: Kris, Mark G., et al.
Publicado: (2023)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
por: Hamada, Akira, et al.
Publicado: (2023)

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

Targeted Therapy in Melanoma and Mechanisms of Resistance
por: Czarnecka, Anna M., et al.
Publicado: (2020)

Ba(OH)(2) Equilibria in the System Ba-O-H-F, With Application to the Formation of Ba(2)YCu(3)O(6.5 + x) From BaF(2)-Precursors
por: Cook, L. P., et al.
Publicado: (2005)

Surgical therapy for pulmonary metastasis of breast cancer
por: Soh, Junichi, et al.
Publicado: (2020)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
por: Suda, Kenichi
Publicado: (2019)

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
por: Lim, Zuan-Fu, et al.
Publicado: (2019)

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
por: Wu, Jiajia, et al.
Publicado: (2022)

Progress on $BaF_{2}$ calorimeters
por: Charpak, Georges, et al.
Publicado: (1991)

Ba/F3 transformation assays
por: Kong, Kathleen, et al.
Publicado: (2017)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hibjbffah981i97omoq28hhavm